title: Clinical and economic burden of peripheral T-cell lymphoma in commercially insured patients in the United States: findings using real-world claims data.
abstract: OBJECTIVE
  This retrospective cohort study utilized real-world claims data to assess the clinical and economic burden of peripheral T-cell lymphoma (PTCL) over the continuum of care in the US.
  
  
  METHODS
  Data were extracted from US administrative claims databases to identify adult patients with PTCL (ICD-9-CM code 202.7X) diagnosed between October 2007 and June 2011. Patients had to have ≥6 months of continuous enrollment before and ≥12 months of continuous enrollment after their index date (date of first PTCL diagnosis). PTCL patients were matched (1:5) by age, sex, region, plan type, payer type, and length of continuous enrollment, to a control group of randomly selected patients without PTCL. Patient-level healthcare resource utilization data and associated costs (in US dollars) were measured. Mean costs per patient per month were determined.
  
  
  RESULTS
  Of 2820 patients with PTCL, 1000 met all inclusion criteria (median age = 57 years; 57.5% male) and were matched to the control group (n = 5000). On an average monthly basis, PTCL patients were hospitalized more frequently (0.07 vs 0.01 admissions; p < 0.0001) and had a longer length of hospital stay (6.4 vs 4.0 days; p < 0.0001) compared with controls. PTCL patients also had higher monthly utilization of pharmacy services (2.85 vs 0.97 prescriptions; p < 0.0001), office visits (1.35 vs 0.34 visits; p < 0.0001), ER visits (0.07 vs 0.02 visits; p < 0.0001), hospice stays (0.05 vs 0.01 stays; p < 0.0001) and other patient services/procedures. Overall, PTCL patients incurred higher average monthly costs per patient compared with control patients ($6327.84 vs $388.39; p < 0.0001), driven mainly by hospitalizations (32.2% of overall costs) and pharmacy services (19.6%).
  
  
  CONCLUSIONS
  This is the first real-world study to quantify healthcare resource utilization, costly treatment, and overall medical expenditure in commercially insured PTCL patients. Better tolerated and more effective treatments may improve disease management and reduce the clinical and economic burden of PTCL.
authors.affiliation: a IMS Health , Fairfax , VA , USA ;|b University of North Carolina at Charlotte , Charlotte , NC , USA ;
authors.forename: Chakkarin
authors.initials: C
authors.lastname: Burudpakdee
authors.affiliation: c Millennium Pharmaceuticals , Inc., Cambridge , MA , USA , a wholly owned subsidiary of Takeda Pharmaceutical Company Limited ;
authors.forename: Huamao Mark
authors.initials: HM
authors.lastname: Lin
authors.affiliation: d NucleusX Market Access , Warren , NJ , USA ;
authors.forename: Weiying
authors.initials: W
authors.lastname: Wang
authors.affiliation: a IMS Health , Fairfax , VA , USA ;
authors.forename: Arpamas
authors.initials: A
authors.lastname: Seetasith
authors.affiliation: c Millennium Pharmaceuticals , Inc., Cambridge , MA , USA , a wholly owned subsidiary of Takeda Pharmaceutical Company Limited ;
authors.forename: Yanyan
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: c Millennium Pharmaceuticals , Inc., Cambridge , MA , USA , a wholly owned subsidiary of Takeda Pharmaceutical Company Limited ;
authors.forename: Vijayveer
authors.initials: V
authors.lastname: Bonthapally
authors.affiliation: e Washington University School of Medicine , St. Louis , MO , USA.
authors.forename: Kenneth R
authors.initials: KR
authors.lastname: Carson
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D003266:Continuity of Patient Care; D017281:Cost of Illness; D005260:Female; D006760:Hospitalization / Q000191:economics*; D006801:Humans; D007345:Insurance Claim Review; D019458:Insurance Coverage; D007348:Insurance, Health; D007902:Length of Stay; D016411:Lymphoma, T-Cell, Peripheral / Q000191:economics*; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014481:United States; D055815:Young Adult
keywords: Claims analysis; Cost of illness; Health resources; Hospitalization; Peripheral T-cell lymphoma; United States